IPN Share Price

Open 65.12 Change Price %
High 66.29 1 Day 0.64 0.98
Low 64.88 1 Week 3.95 6.39
Close 65.74 1 Month 2.90 4.61
Volume 119673 1 Year 6.19 10.39
52 Week High 66.29
52 Week Low 45.31
IPN Important Levels
Resistance 2 67.05
Resistance 1 66.51
Pivot 65.64
Support 1 64.97
Support 2 64.43
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
SOI 1.38 11.29%
SOI 1.38 11.29%
SOI 1.38 11.29%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
More..
EPA France Top Gainers Stocks
ALALO 0.04 33.33%
APAM 33.78 15.72%
APAM 33.78 15.72%
ALSAS 6.29 15.62%
MLLOI 3.80 15.15%
AVQ 0.16 14.29%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
MLCAC 8.00 -21.95%
MLDEX 0.30 -18.92%
AVT 0.05 -16.67%
AVT 0.05 -16.67%
AVT 0.05 -16.67%
AVT 0.05 -16.67%
VRNL 0.51 -12.07%
EBPF 85.50 -10.00%
ALMAS 0.79 -9.20%
TONN 1.01 -8.18%
More..

Ipsen (EPA: IPN)

IPN Technical Analysis 5
As on 9th Dec 2016 IPN Share Price closed @ 65.74 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 56.11 & Strong Buy for SHORT-TERM with Stoploss of 62.65 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPN Target for December
1st Target up-side 66.59
2nd Target up-side 68.25
3rd Target up-side 69.92
1st Target down-side 61.83
2nd Target down-side 60.17
3rd Target down-side 58.5
IPN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ipsen.com
IPN Address
IPN
65, quai Georges Gorse
Cedex
Boulogne-Billancourt, 92650
France
Phone: 33 1 58 33 50 00
Fax: 33 1 58 33 50 01
IPN Latest News
Ipsen Needs Its Big Swing In Oncology To Connect   Seeking Alpha   - 31st Aug 16
Ipsen Biopharmaceuticals, Inc. announces FDA approval of Dysport ...   PR Newswire (press release)   - 01st Aug 16
Ipsen's First Half 2016 Results   Business Wire (press release)   - 28th Jul 16
The Ipsen Group Launches an Employee Shareholding Plan   Business Wire (press release)   - 06th Jun 16
Ipsen suits Exelixis in potential $855M ex-US license agreement   BioWorld Online   - 02nd Mar 16
Ipsen Seeks CEO as It Splits Top Roles, Deputy CEO to Leave   Bloomberg   - 16th Feb 16
Ipsen to Step Up Deal-Making, Scout for New Cancer Products   Bloomberg   - 19th Jan 16
Ipsen Aims to Boost U.S. Sales With More Workers and New Drugs   Bloomberg   - 12th Mar 15
Nestle's Galderma Deepens Ipsen Alliance for Wrinkle Drug   Bloomberg   - 11th Jul 14
Mayroy Sells 7% Stake In French Pharma Co. Ipsen   Law360 (subscription)   - 21st Mar 14
Interactive Technical Analysis Chart Ipsen ( IPN EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ipsen
IPN Business Profile
Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.